



Reasonably Random Synthetic Biology at Amyris

Tim Gardner
Director, Research Programs & Operations
October 27, 2010

- ▶ Amyris is an integrated renewable products company producing advanced renewable fuels and chemicals
- ▶ Founded in 2003 on principle of social responsibility: use our know-how to address biggest health and environmental challenges
- ▶ Public company (IPO September 2010) with R&D, Manufacturing and Distribution facilities in the Emeryville, CA, Campinas, Brazil & Chicago, IL



Amyris' founding product: Artemisinin

Artemisinin is 95% effective against malaria

The Challenge: Supplying Artemisinin Anti-Malarials

Malaria causes:

1 to 3 million deaths per year

Treating malaria would require:

300 to 500 million treatments per year



Artemisinin treatments needed:


225 to 400 tons of artemisinin per year

This would require:

6,000,000 tons of plant material

Total Chemical Synthesis
too expensive


Non-profit effort to manufacture Artemisinin



Artemisa annua




Strain performance targets reached



- Sanofi-aventis now ramping production, formulation and product stability testing
- Aim for world-wide distribution in 2012.


Isoprenoid technology platform capable of making more than 50,000 molecules






Phase-contrast micrograph of Amyris engineered microbes producing precursor to Amyris Renewable Diesel

- Hydrocarbons, not alcohols or esters
- Can be used in existing engines with no performance trade-offs
- Superior environmental profile
 - substantially lower greenhouse gas emissions than petroleum
 - No sulfur
 - Lower particulates and NOx
- Can be delivered using existing distribution infrastructure

Diesel production



Amyris Renewable Diesel: a better fuel



Additional benefits of Amyris renewable diesel compared to #2-Diesel


- 90%+ lower greenhouse gas emissions
- No sulfur & produces lower NOx and particulate emissions
- Registered with the EPA for 20% blends

Note: Amyris diesel will be used in blends with conventional fuels; values shown for Amyris diesel is for our biomass derived blending component; SME = Soy Methyl Esters

>\$1 Trillion dollar market accessible



fermentation



→ biology

→ chemistry



- Renewable diesel
 - “plug-in” fuels
 - meets or exceeds stds
 - substantially lower emissions

\$809B



- Lubricants
 - family of base oils
 - designed to be high performance

\$48B



- Consumer products
 - detergents
 - Cosmetics
 - fragrances

>\$50B



- Polymers
 - adhesives
 - oxygen scavenger
 - toughening agent


\$337B



- Other applications
 - crop protection
 - many others


By combining biology and chemistry, Biofene becomes a building block of renewable products for a diverse set of applications

Lower cost of production enables access to larger markets




Low-cost production drives everything in strain R&D

Capital cost-saving opportunities



2M ton/yr plant



Engineering decisions drive strain performance criteria



Multi-parameter strain optimization problem

- yield
- productivity
- reduced media supplements
- temperature
- biocatalyst stability
- GMM certification


For fuel synthesis we aim to direct >90% of cell resources to the synthesis of byproducts under stringent productivity, temperature, and media conditions

like getting a toddler to eat salad




But we've made rapid progress


Fuels strain improvement since program start



How we got there




What can we learn from the mutants?



Illumina paired-end sequencing performed by Prognosis, Sequence assembly & analysis by Amyris

Mutant family tree and performance gains



What about rational engineering?

Synthetic Biology: the dream of plug and play biology



Are electronics and machines the right paradigm?

The neutral chassis hypothesis



Add a little
synthetic
biology




Biology is designed by natural selection




It works, but it's not always pretty


Too many parts kinda complexity




Promoter strength varies depending on its insertion site

Bar Chart






Farnesene Pathway




4 diverse hybrid haploids.
Select for production

Impact of diversity on Mevalonate production

Fold increase in mevalonate titer over reference



Frequencies for top and bottom Mevalonate pools



A practical approach

Pathway PoC

Pathway Optimization

① *Rational*

**Stoichiometry & mRNA
expression**

Routine

We always start here

② *Semi-rational
Random*

Enzyme kinetics

Doable but hard

We have targeted activities
here when bottlenecks
become clear

③ *Random*


**Context-effects & post-
transcriptional regulation**

Shooting in the dark

This is where most of the
strain improvement
“action” is.

1. Rational: Modeling / Isotopomers

Yeast metabolic database



The screenshot shows the 'plato' Metabolic Models database interface. At the top, there are navigation buttons: Logout (Timothy Gardner), Reactions, Compounds, Download, Upload, and Previous Models. Below these are search fields for ID, Gene Name, Compound (Abbr.), and Reaction (Regex), along with checkboxes for 'S. cerevisiae' and 'Other organisms'. A model selection dropdown is set to '2.1.59' with a 'switch model' button and a note '901 out of 1118 reactions. export filtered set'.

ID	Gene	ORF	Reaction	E.C. Number	ΔG° (kcal/mol)	SGD viability	Pathway	Bal.	Organism
1	GLK1	YCL040W	GLC + ATP -> H + G6P + ADP	2.7.1.2	-13.319209	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
2	GLK1	YCL040W	MAN + ATP -> H + MAN6P + ADP	2.7.1.2		VIABLE	Mannose metabolism	Y	Saccharomyces cerevisiae
3	HXK1	YFR053C	GLC + ATP -> H + G6P + ADP	2.7.1.1	-13.319209	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
4	HXK1	YFR053C	MAN + ATP -> H + MAN6P + ADP	2.7.1.1		VIABLE	Mannose metabolism	Y	Saccharomyces cerevisiae
5	HXK1	YFR053C	ATP + FRU -> H + ADP + F6P	2.7.1.1	-13.328609	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
6	HXK2	YGL253W	GLC + ATP -> H + G6P + ADP	2.7.1.1	-13.319209	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
7	HXK2	YGL253W	MAN + ATP -> H + MAN6P + ADP	2.7.1.1		VIABLE	Mannose metabolism	Y	Saccharomyces cerevisiae
8	HXK2	YGL253W	ATP + FRU -> H + ADP + F6P	2.7.1.1	-13.328609	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
9	PGI1	YBR196C	G6P <-> F6P	5.3.1.9	-0.3474	INVIABLE	Glycolysis	Y	Saccharomyces cerevisiae
10	YMR099C	YMR099C	G6P <-> BDG6P	5.3.1.9	-1e-05	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
11	PGI1	YBR196C	BDG6P <-> F6P	5.3.1.9	-0.34739	INVIABLE	Glycolysis	Y	Saccharomyces cerevisiae
12	PFK1	YMR205C	F6P + ATP -> H + FBP + ADP	2.7.1.11	-13.324332	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
13	PFK1	YGR240C	F6P + ATP -> H + FBP + ADP	2.7.1.11	-13.324332	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
14	FBA1	YKL060C	FBP <-> DHAP + GAP	4.1.2.13	1.395244	INVIABLE	Glycolysis	Y	Saccharomyces cerevisiae
15	TPI1	YDR050C	DHAP <-> GAP	5.3.1.1	0.458	INVIABLE	Glycolysis	Y	Saccharomyces cerevisiae
16	TDH1	YJL052W	GAP + PI + NAD <-> H + NADH + 13PDG	1.2.1.12	-4.730974	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae
17	TDH2	YIR009C	GAP + PI + NAD <-> H + NADH + 13PDG	1.2.1.12	-4.730974	VIABLE	Glycolysis	Y	Saccharomyces cerevisiae

The detailed view for reaction ID 4 shows the following information:

- ID:** 4
- E.C. Number:** 2.7.1.1 (BRENDA)
- Pathway:** Mannose metabolism
- Standard Name:** HXK1 (SGD)
- Systematic Name:** YFR053C
- SGD Viability:** VIABLE
- SGD Notes:** Hexokinase isoenzyme 1, a cytosolic protein that catalyzes phosphorylation of glucose during glucose metabolism; expression is highest during growth on non-glucose carbon sources; glucose-induced repression involves the hexokinase Hxk2p
- Organism:** Saccharomyces cerevisiae
- Reaction:** MAN + ATP -> H + MAN6P + ADP
- Transport Reaction:**
- Balanced Checked:**


Input

- Public models
- Yeastcyc
- Amyris knowledge
- Experimental data

Output

- Balanced models
- Simulatable models
- Matlab, Excel, GAMS format


2. & 3. Industrialize strain improvement



Continuous process improvement is critical


Assuming constant absolute yield gain per improved mutant strain.

- S/N will drop as yield increases.
- So too must CV.




The value of process control

Original strain screening assay



New assay





The reward:

Overall screening process
CV <4%


Enables detection of 4% improvements w/ 5% FN and 5% FPs through 2 tiered screen

HT screening pipeline

Process improvement is easier said than done




Diagnosing sources of variation




Better decisions via informatics integration

LIMS systems is identifying and eliminating sources of error




Multivariate optimization – picking winners

Informatics integration is critical to good decisions (get data out of silos)




Informatics integration enables assessment of stress resistance




Let the data guide

Use empirical data mining to guide library construction, screening conditions, process dev.


Energy Charge




MRM Analysis




Flux Leader Board




Metabolite Monitoring



Proteomic Analysis



T-Omic Clustering of Physiology



- **Rational engineering gets the ball rolling**
- **Industrialization enables rapid strain optimization**
 - Harnessing nature’s way of “thinking”: randomness and diversity
 - We are doing in 4 years what used to take 12
- **Continuous process improvement is critical to the success of an industrial platform**
 - Informatics is fundamental
 - Data mining & omics is fundamental



**Thanks to the >200 folks in R&D
contributing to our success**